anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ventricular arrhythmias are the leading cause of sudden cardiac death in patients after myocardial infarction (MI). Connexin43 (Cx43) is the most important gap junction channel-forming protein in cardiomyocytes. Dysfunction of Cx43 contributes to impaired myocardial conduction and the development of ventricular arrhythmias. Following an MI, Cx43 undergoes structural remodeling, including expression abnormalities, and redistribution. These alterations detrimentally affect intercellular communication and electrical conduction within the myocardium, thereby increasing the susceptibility to post-infarction ventricular arrhythmias. Emerging evidence suggests that post-translational modifications play essential roles in Cx43 regulation after MI. Therefore, Cx43-targeted management has the potential to be a promising protective strategy for the prevention and treatment of post infarction ventricular arrhythmias. In this article, we primarily reviewed the regulatory mechanisms of Cx43 mediated post-translational modifications on post-infarction ventricular arrhythmias. Furthermore, Cx43-targeted therapy have also been discussed, providing insights into an innovative treatment strategy for ventricular arrhythmias after MI.
Subjects will have their right eye treated with 5% Povidone Iodine per standard institutional protocol prior to receiving their intravitreal injection (2 drops of PI followed by application of 3.5% non-preserved lidocaine gel for 10 minutes, followed by 1 drop of PI for 30 seconds prior to injection). Subjects will have their left eye treated with Avenova per the same application protocol as PI prior to receiving their intravitreal injection. Prior to and following disinfecting both eyes but before the injection, a physician will gently swab the inferior conjunctival fornix (white part of each eye below the lower eye lid) with an ocular brush. Swabs will be cultured to compare bacterial counts. Subjects will be asked to complete a questionnaire regarding comfort of the disinfectant and injection procedure in general immediately following the injection and 1-2 hours post-injection.
PURPOSE: To obtain an ultraviolet absorbing agent containing neosakuranin existing in the bark of cherry tree as an active component, exhibiting excellent ultraviolet absorbing action in both ultraviolet A and B regions and having high safety and to prepare a cosmetic containing the absorbing agent. CONSTITUTION: This ultraviolet absorbing agent composed of neosakuranin is produced e.g. by adding 1-20 pts. of a polar solvent to 1 pt. of the bark of cherry tree and extracting at room temperature or by heating at a temperature near the boiling point of the solvent. A cosmetic having excellent effect to protect the skin from ultraviolet rays can be produced by compounding the ultraviolet absorbing agent. The amount of the ultraviolet absorbing agent to be compounded to the cosmetic is preferably 0.1-5wt.%. Neosakuranin has absorptions in both ultraviolet A and B regions. The percent absorption of the absorption peak (at 370nm) in the ultraviolet A region is as high as 700 and the agent is suitable as an ultraviolet absorbing agent. The cherry is e.g. Yoshino cherry, Japanese hill cherry or Oshima cherry (Prunus larmesiana).  Above all, Oshima cherry is preferable because of its high neosakuranin content. The cosmetic is continuously usable over a long period.
Chronic obstructive pulmonary disease (COPD) is comprised of histopathological alterations such as pulmonary emphysema and peribronchial fibrosis. Matrix metalloproteinase 9 (MMP-9) is one of the key enzymes involved in both types of tissue remodeling during the development of lung damage. In recent studies, it was demonstrated that deflamin, a protein component extracted from Lupinus albus, markedly inhibits the catalytic activity of MMP-9 in experimental models of colon adenocarcinoma and ulcerative colitis. Therefore, in the present study, we investigated for the first time the biological effect of deflamin in a murine COPD model induced by chronic exposure to ozone. Ozone exposure was carried out in C57BL/6 mice twice a week for six weeks for 3 h each time, and the treated group was orally administered deflamin (20 mg/kg body weight) after each ozone exposure. The histological results showed that deflamin attenuated pulmonary emphysema and peribronchial fibrosis, as evidenced by H&E and Masson's trichrome staining. Furthermore, deflamin administration significantly decreased MMP-9 activity, as assessed by fluorogenic substrate assay and gelatin zymography. Interestingly, bioinformatic analysis reveals a plausible interaction between deflamin and MMP-9. Collectively, our findings demonstrate the therapeutic potential of deflamin in a COPD murine model, and suggest that the attenuation of the development of lung tissue damage occurs by deflamin-regulated MMP-9 catalytic activity.
Unequivocal evidence of recurrence (progressive disease) on contrast-enhanced brain CT or MRI as defined by RANO criteria, or have documented recurrent glioma on diagnostic biopsy. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
The Exercise intervention will persist of a 20-minute bout of moderate intensity aerobic exercise which by definition is 40-65% of Maximum Heart Rate. Exercise consisted of a 2-minute warm-up, followed by 15 min of walking at a rate, which will allow you to reach 2/3 of your max heart rate, and then a 3-minute cool down on a treadmill equaling 20 minutes. Heart Rate will be examined with Polar Wearlink coded Heart Rate monitors to attain the specific exercise intensity.
PURPOSE:To obtain a sheet like shell membrane capable of being kept constant in quality, capable of being set to an arbitrary shape and size and possible in mass production, by bonding the powdery eggshell membrane to the meshes of entangled fibers. CONSTITUTION:A powdery eggshell membrane is dispersed in an aqueous suspension of proper plant fibers or a mixture of said fibers and other fibers to prepare a so called paper stock solution. These fiber materials are pref. swollen in the paper stock solution. In a mixing ratio (on a wt. basis) of the eggshell membrane and fibers in the paper stock solution, the shell membrane is pref. made much because the bonding ratio of the particles of the eggshell membrane to the surfaces of the fiber materials becomes high but the content of the eggshell membrane is about 50-80% in usual and can be increased to the max. of about 95%. Further, a size (binder), a surfactant, a dispersant, a defoaming agent and a thickener may be added to the paper stock solution if necessary. The paper stock solution thus prepared is formed into a sheet in the same way as a Japanese paper making process.
The invention discloses a neutrality monoclonal antibody against botulinum neurotoxin type B and also discloses a humanized modifier of the antibody. The antibody is prepared through the following method: firstly, the CDR region, variable region, IgG part or full gene of the antibody is prepared through molecular biological methods or other methods and is expressed in prokaryotic cells such as colibacillus, eukaryote cells such as yeast, or insect cells, vegetable cells or mammal cells such as CHO; and the antibody is obtained through purification. The antibody is characterized by strong specific neutralization activity and high affinity. In addition, the humanized antibody is characterized by low side and toxic effect. The neutrality monoclonal antibody and the humanized modifier of the antibody are suitable for the first aid treatment of botulinum neurotoxin type B intoxication and also for the detection of botulinum neurotoxin type B. Therefore, the antibody and the humanized modifier thereof have good application prospect.
A system is described that generates insights on the consumption or usage behavior of a product by analyzing the real-time usage of the product by one or more users. The product is placed on the measuring device for continuous monitoring of the usage of the product by those one or more users in real-time. The measuring device includes a sensor unit that generates weigh data, motion data, location data, and time consumed data of the product and transmits to a computing device. A communication device records the consumption or usage of the product by a user, along with feedback from the user. The computing device generates insights based on the sensed data generated by the measuring device, and recording and feedback at the communication device. The computing device generates reports—one for the user, and one for a merchant of the product and/or similar products—including respective insights.
PROBLEM TO BE SOLVED: To obtain a contrast medium extremely safe, not forming a lump in the gastrointestinal tract, providing a satisfactory X-ray image, by making the medium include ferric pyrophosphate-dispersed oils and fats as an active ingredient. SOLUTION: This contrast medium comprising oils and fats (e.g. soybean oil, olive oil, a colza oil, etc.,) into which ferric pyrophosphate (a substance in which iron and phosphoric acid are subjected to chelate bond strongly) as an active ingredient. Consequently, the contrast medium is provided with proper viscosity and has properties suitable for a contrast medium, namely properties not disturbing uniformity in gastrointestinal tract, bladder, urinary tract, etc., and sufficiently adhering to mucosa. In the objective contrast medium, the existence of iron is adjusted to >=0.1% by weight ratio. In use, preferably the contrast medium is mixed with a solvent such as water, an alcohol or the like, an emulsifying agent, and emulsion, glycerol, dextrin, a cellulose, a thickening agent, etc., so as to raise affinity for mucosa and th adjust osmotic pressure so that mucosa is not excessively irritated.
Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
NEW MATERIAL:N-(beta-Chloro-4-methylcinnamoyl)-L-phenylalanine expressed by the formula. USE:An absorbefacient, useful for pharmaceutically active substances, especially absorbefacient for insulin and having excellent effects and safety. PREPARATION:L-Phenylalanine is reacted with beta-chloro-4-methylcinnamoyl chloride in the presence of sodium hydroxide in a solvent, such as acetone, at ordinary temperature to afford the aimed compound expressed by the formula. The above-mentioned compound as an active ingredient is blended and a pharmaceutical is prepared by a conventional method and administered in 0.2-2,000mg dose a day. This absorbefacient is used in an amount of, e.g. 0.1-2,000mg based on 25 units insulin.
Calcium carbonate is obtained from freshly broken egg-shells by washing the shells to remove egg-white and yolk therefrom, germicidally treating the shells, then washing to remove any germicidal odour therefrom optionally drying, then immersing the shells in a hot alkaline solution to effect solution of the membrane, removing the solution, washing the shells (the washing including treatment with acid) to remove all traces of alkali therefrom, and finally drying the shells quickly to prevent bacteriological and enzymatic changes therein.  The removal of the egg white and yolk may be achieved by centrifugal washing and drying coupled with an intermediate treatment with a suitable germicide such as sodium hypochlorite or hydrogen peroxide.  The shell is rapidly dried at preferably 180 DEG  F. to 210 DEG  F., preferably for 15 to 30 minutes.  The dry sterile egg-shell is immersed in a hot solution of a weak alkali and/or alkaline salts, e.g. NaOH, to effect complete removal of any remaining trace of egg-white and solution of the egg-shell membrane.  Any entrained alkali is removed by water washing and the use of a low concentration of a mild acid such as acetic acid, and a final removal of occluded odours may be effected by using a mild oxidizing agent such as sodium hypochlorite or hydrogen peroxide. The treated egg-shells may be stored, or finely ground. Grinding may be either by wet grinding in the presence of a low concentration of a mildly acetic substance, e.g. acetic acid, or of a low concentration of an oxidizing agent, e.g. sodium hypochlorite, or by dry grinding to achieve particle sizes of mostly below 20 microns. A combination of both types of grinding may be used.  The powder product may be used to replace creta-preparata as a nutritional supplement of calcium in flour as used for bread-making and other food purposes.  In admixture with various powdered forms of calcium carbonate in suitable proportions, the powder confers "free-running" properties not possessed by other powder forms of calcium carbonate by themselves.  Such free-running mixtures may be used as a nutritional supplement in flour, and also in the preparation of toothpastes and powders, and cosmetics.  The powder may also be used as lubricants and as fillers.  Reference has been directed by the Comptroller to Specification 790,073.ALSO:Calcium carbonate from waste egg-shells (see Division C1) may be mixed with various powdered forms of calcium carbonate to confer "free-running" properties not possessed by the powder forms of calcium carbonate by themselves and the mixture may be used in the preparation of toothpastes powders, and cosmetics.  Reference has been directed by the Comptroller to Specification 790,073.
Methods are provided for producing compositions, e.g. pastes or clays, which rapidly set into high-strength calcium phosphate products. In the subject methods, dry reactants that include calcium and phosphate sources, as well as a monovalent cation dihydrogen phosphate salt, are combined with a setting fluid and the combined reactants are mixed to produce the settable composition. A feature of the invention is that cements rapidly set into high strength product compositions. Also provided are the compositions themselves as well as kits for preparing the same. The subject methods and compositions produced thereby find use in a variety of applications, including hard tissue repair applications.
Symptomatic chronic atherosclerotic gastrointestinal ischemia (CGI) is an uncommon, potentially underdiagnosed condition caused by fixed stenosis or occlusion of in most conditions at least one of the three gastrointestinal arteries. Atherosclerosis is a predisposing factor for CGI. Clinical symptoms can vary widely. Typical symptoms are postprandial abdominal pain, unintended weight loss and food avoidance. But atypical abdominal pain such as exercise related pain, diarrhoea and nausea can also indicate CGI. The use of endovascular techniques for revascularization of chronic stenosis and occlusions of the gastrointestinal arteries has rapidly increased and endovascular therapy with stenting has become the most common method chosen for revascularization, having replaced open surgery with its associated morbidity and mortality. Nowadays standard care in significant chronic gastrointestinal ischemia is the use of bare metal stents although the patency of these stents is not very high. According retrospective data the patency of covered stents is significantly higher compared to bare metal stents. One likely explanation for these lower restenosis and re-intervention rates observed with covered stents is the established barrier to tissue ingrowth. Only recent retrospective data about this topic is available but the expectancy in this prospective study is that the patency of covered stents is indeed higher compared to metal stents.
This is a single blinded randomized controlled trial, will be conducted at Ankara Yıldırım Beyazıt UniversityYenimahalle Education and Research Hospital. Evaluations regarding the parameters and inclusion criteria at the stage of diagnosis will be carried out by the Specialist Physician, exercise therapy and taping practices by the Specialist Physiotherapist, and the MRI measurements by the Specialist Radiologist. Fixed probability stratified randomization method will be preferred in order to ensure proportional gender distribution in the formation of groups and participants will be divided into 3 groups. An exercise program that includes stretching, strengthening and balance exercises accompanied by physiotherapist in the clinic will be applied to all individuals participating in the study for 2 times/week X 6 weeks (12 sessions). Only the exercise program will be applied to the first group. To the second group; McConnell patellar taping technique will be applied using rigid tape(Leukotape® P Rigid Strapping Tape, 38 mm X 10 m, USA) in addition to the exercise program in each session.To the third group; femoral lateral rotation taping technique will be applied using rigid tape in addition to the exercise program. Patients' patellar maltraction, pain function, balance, and quality of life will be assessed before and after treatment with MRI and clinical testing.
First of all, 'true' VO2max of all subjects was calculated using non-exercise regression equation and one mile walk test. Variables used for the VO2max regression equation included BMI, age (years), gender (Male=1, Female=0) and physical activity rating scale. On the same visit, the subjects also performed one mile walk test. After the completion of test, pulse rate of subjects was calculated in beats per minute. The VO2max after the test was measured using the VO2max aerobic capacity calculator. Variables required were age, gender, weight, total time taken to complete test and pulse rate at test completion.

'True' VO2max accepted was the highest value obtained from non-exercise regression equation and one mile walk test On the 2nd visit, the participants performed Modified Bruce Submaximal Exercise test depending upon their fitness level and Mankato Submaximal Exercise test in counter balanced order with 30 minutes rest in between
Adult men and women between 18 and 55. No prior history of traumatic brain injury. Experienced taking hemp-derived botanicals.
The main goal of the project is to define specific mutational signatures of endometrial cancer (EC) patients using whole-exome sequencing technology. The relationship between mutational profiles and molecular classification of endometrial cancer will be analyzed in order to improve the stratification of these patients, especially those classified as having a non-specific molecular profile or p53 mutations. At the same time, the association between the dominant mutational profiles of EC patients with the prevalence of lifestyle risk factors such as obesity/BMI, hypertension and diabetes mellitus will be investigated and their incidence is becoming more prevalent in the modern population. Associations between the occurrence of specific mutation profiles with risk factors will be sought and their role in influencing the genetic profile of EC patients will be analyzed. Another aim of the project is to find relationships between specific mutational profiles of patients with the extent of staging lymphadenectomy, which could help to decide the extent of this surgery, which subsequently affects the quality of life of patients, especially in patients with high BMI. The final aim of the project is to establish a methodology to detect mutations arising from dominant specific mutational profiles in circulating tumor DNA (ctDNA) to monitor potential recurrence in patients at high risk of developing and recurrent disease. Overall, the main contribution of the project will be a detailed understanding of the relationship of the genetic profile of EC patients with their molecular subtype, the extent of staging lymphadenectomy and, most importantly, their impact related to the presence of lifestyle risk factors. These factors may be related to the presence of specific dominant mutational profiles subsequently serving as a tool for prognosis, prevention, risk of recurrence but also potential therapeutic targets in women with the presence of any of the lifestyle risk factors.
PURPOSE:To obtain a new bioactive polypeptide having an excellent antibacterial effect, almost free from toxicity and useful as an antibacterial agent, etc., by isolating a polypeptide having a specified amino acid sequence from a culture supernatant of cells derived from the embryo of latrine flash fly. CONSTITUTION:Cells derived from the embryo of latrine flash fly are seeded in a cluture medium, then subcultured at 25 deg.C for 7-10 day and subsequently centrifuged to separate the culture supernatant. To the resultant supernatant, a phosphate buffer (pH 6.0) is added and the obtained mixture is then passed through a cation exchange column followed by elution of adsorbates. Fractions showing antibacterial activities are collected and then heat treated at 100 deg.C for 10min. The resultant precipitate is removed by centrifugation and the obtained supernatant is concentrated by ultrafiltration. The concentrated solution is subjected to gel filtration and reverse phase high performance liquid chromtography in order for purification, thus obtaining the objective bioactive polypeptide represented by an amino acid sequence of the formula and having an antibacterial effect.
The study will be carried out in close collaboration with the Director of the Expertise and Sports Performance Center (CREPS) of Montpellier. Compared to the athlete's usual seasonal training program, his participation in research will be limited to two visits to the Montpellier University Hospital where a quadriceps micro biopsy and a blood test will be carried out. During the first visit to the Montpellier University Hospital, a short clinical examination will also be carried out including an interrogation on his medical history, his consumption of drugs, alcohol, tobacco as well as the measurement of his weight and height and a simple cardiopulmonary auscultation. As part of the standard care for athletes, the training program carried out at CREPS Montpellier will be defined by weekly strength exercises to increase muscle mass. As part of this program and approximately one week before the two visits to the Montpellier University Hospital, an evaluation of the mass and the contractile function of the muscle will be carried out. The measurement of muscle mass will be carried out by Magnetic Resonance Imaging. The contractile function of the quadriceps muscle will be measured on a weight bench equipped with a dynamometer at the CREPS in Montpellier. Data from these assessments will be collected as part of the research.

This study will allow the synthesis of a muscular organoid, representative of an in vivo muscle, allowing the in vitro study of muscular lesions associated with the rupture of muscle fibres and the activation of satellite cells allowing the regeneration of damaged fibres. This in vitro muscle model will allow us to evaluate the inter-individual variability of the muscle response to the same mechanical stress and to study its link with the dynamic epigenetic changes specific to each athlete. This study will make it possible, for the first time, to evaluate whether an epigenetic signature predictive of the muscular response to an injury could also be found in blood cells.